Genotoxicity testing is an important part of standard safety testing strategies. Animal studies have always been a key component, either as a mandatory part of the regulatory test battery, or to follow-up questionable in vitro findings. The strengths and weaknesses of in vivo assays is a continuous matter of debate, including their capacity to predict (human) carcinogenicity. We have therefore analysed the sensitivity of five routinely used in vivo tests to determine, in addition to other aspects, which tests or combination of tests best identify 73 chemicals classified as IARC Group 1 and 2A carcinogens. The in vivo tests included the micronucleus (MN), unscheduled DNA synthesis (UDS), comet, Pig-a and transgenic rodent assays (TGR). The individual assays detect 74.2% (49/66, MN), 64.3% (9/14, UDS), 92.1% (35/38, comet), 82.4% (14/17, Pig-a) and 90.3% (28/31, TGR) of the probable and confirmed human carcinogens that were tested in these assays. Combining assays that cover different genotoxicity endpoints and multiple tissues, e.g. the bone marrow MN and the liver comet assays, increases the sensitivity further (to 94%). Correlations in terms of organ-specificity for these assays with human cancer target organs revealed only a limited correlation for the hematopoietic system but not for other organs. The data supports the use of the comet and TGR assays for detection of 'site-of-first-contact' genotoxicants, but these chemicals were generally also detected in assays that measure genotoxicity in tissues not directly exposed, e.g. liver and the hematopoietic system. In conclusion, our evaluation confirmed a high sensitivity of the five in vivo genotoxicity assays for prediction of human carcinogens, which can be further increased by combining assays. Moreover, the addition of the comet to the in vivo MN test would identify all DNA reactive human carcinogens. Importantly, integration of some of the study readouts into one experiment is an animal-saving alternative to performing separate experiments.
Introduction
Historically, in vivo genotoxicity assays have been used exclusively for hazard identification, as part of the standard testing battery for pharmaceuticals and for industrial chemicals utilised in products with consumer-relevant exposures. The field is, however, moving towards a comprehensive risk assessment approach, requiring information on a compound's genotoxic mode of action (MoA), evaluation of its effect on relevant tissues and endpoints, as well as quantitative assessment of the dose-response relationship (1) . In addition, recent changes in the guidelines for development of pharmaceuticals, ICH S2R1, acknowledge the utility of a combination of two in vivo assays performed in different tissues as part of standard genotoxicity testing (2) . Importantly, the choice of in vivo assays (and their potential combination) as well as tissues is guided by an increased attention to MoA and route of exposure considerations.
The development of additional in vivo assays, coupled with validation efforts (3) (4) (5) (6) (7) (8) (9) , has led to increasingly large data sets that were utilised for the analysis presented here. In addition to the micronucleus (MN; OECD 474) and unscheduled DNA synthesis (UDS; OECD 482) assays, which were established many years ago and detect chromosome damage (clastogenicity or aneugenicity) in bone marrow cells and DNA damage in liver cells, respectively, we evaluated the predictivity of three more recent methods for International Agency for Research on Cancer (IARC) Group 1 and 2A compounds. The first one, the comet assay (OECD 489), similar to the UDS assay, detects primary DNA damage but is not limited to liver cells. It can be performed in various organs and does not require cell division (6, 8, (10) (11) (12) (13) , which differentiates it from all other assays. The second new method, the TGR assay (OECD 488), primarily detects gene mutations and can also be performed in virtually any tissue. The most recently developed method, the Pig-a assay, detects gene mutations in blood cells. In contrast to the TGR assay, it is relatively easy to perform and can be integrated into repeat dose general toxicity studies (e.g. 28-day treatment) but is currently limited to only one tissue (14, 15) . The introduction of these assays has enabled novel study designs and testing strategies, e.g. the evaluation of genotoxic responses in different target organs, such as those with a high exposure to the test compound (e.g. due to accumulation), organs that extensively metabolise the chemical, or organs that are located at the 'site-of-first-contact' of the test compound with the body.
In 1990, Shelby and Zeiger compiled available in vitro and in vivo genetic toxicology data for human carcinogens and evaluated the correlation between human carcinogenicity and genotoxicity assays (16) . They concluded that the highest safety concern for potential human carcinogens is warranted when Salmonella mutagens and rodent clastogens (causing bone marrow chromosomal aberrations or MN) show carcinogenic activity in rodents. The availability of new in vivo assays and more recent data allow for a critical appraisal of the currently available in vivo methods. The present work therefore focuses on the predictive capacity of five in vivo genotoxicity assays, namely, the MN, UDS, comet, Pig-a and TGR: i.e. their ability to identify IARC Group 1 and 2A carcinogens. We show which in vivo assay or which combination of in vivo assays correlates best with positive carcinogenicity outcomes. To do this, we collected published data for carcinogens with known (Group 1) and probable (Group 2A) human relevance, as classified by the IARC. At the time of our evaluation, the IARC monographs included 116 agents that are carcinogenic to humans (Group 1) and 73 agents that are probably carcinogenic to humans (Group 2A) (data as of 23 Oct 2015; IARC website). Our analysis focused on 73 individual chemicals, as opposed to 'agents' (including, e.g. mixtures like coal tar-for details, see the Methods Section). Of the 73 chemicals, 33 belong to Group 1 and 40 to Group 2A carcinogens (Table 1 ). An initial evaluation of the use of each assay was made, providing information on how many of the 73 chemicals were tested in each of the five assays. Furthermore, we have addressed the following questions:
• Which test or combination of tests detects IARC 1 and 2A carcinogens best? Would relevant human carcinogens be missed with a combination of bone marrow in vivo MN and in vivo liver comet assays? • Is there any combination of assays that significantly outperforms other possible combinations? As an example, one might assume that the TGR, which detects gene mutations, is an especially valuable add-on to the in vivo MN assay, which detects chromosomal damage.
• If a chemical is assessed in several organs in the comet assay, are genotoxic effects at the 'site-of-first-contact' detected with higher sensitivity than in other organs tested, e.g. the liver? • Is there a correlation between organ-specific genotoxicity and organ-specific carcinogenicity? For example, one might assume that chemicals that induce chromosomal aberrations in the bone marrow (positive in vivo MN test) or DNA damage in the liver (positive in vivo UDS assay) can lead to leukaemia-type or liver cancers, respectively.
Methods

Data collection
The IARC has classified chemicals or combinations of chemicals as being causally associated with cancer in humans. We focussed on Group 1 and Group 2A chemicals. Group 1 chemicals (carcinogenic to humans) are defined as follows: 'Sufficient evidence in humans OR exceptionally, sufficient evidence in animals AND strong evidence in exposed humans that the agent acts through a relevant mechanism OR clearly belongs, based on mechanistic considerations, to a class of agents for which one or more members have been classified in Group 1'. Group 2A chemicals (probably carcinogenic to humans) are defined as follows: 'Limited in humans AND sufficient in animals OR inadequate in humans AND sufficient in animals AND strong evidence that carcinogenesis is mediated by a mechanism that also operates in humans. OR exceptionally, an agent may be classified in this category solely on the basis of limited evidence in humans. OR clearly belongs, based on mechanistic considerations, to a class of agents for which one or more members have been classified in Group 2A' (17) ( Table 1-additional information on the  tests and references are listed in Supplementary Table 1, available at Mutagenesis Online). The selection of chemicals was frozen as of October 23, 2015 ; however, the literature searches for in vivo genotoxicity data continued after this date. The term 'agent' used by the IARC refers to any entity or circumstance that is subject to evaluation in a monograph and includes specific chemicals, groups of related chemicals, complex mixtures, occupational or environmental exposures, cultural or behavioural practices, biological organisms and physical agents. For the purpose of our analysis, only 'specific chemicals', i.e. individual chemicals in contrast to mixtures, were considered. The exceptions to this included (i) plutonium, which is a specific chemical but we assumed that its toxic MoA is mainly related to radioactive decay; (ii) 8-methoxypsoralen, since it is only genotoxic after photo-activation (18); (iii) 2,3,4,7,8-pentachlorodibenzofuran and 3,4,5,3′,4′-pentachlorobiphenyl since they are considered to act via dioxin-like [2,3,7,8-tetrachlorodibenzo-p-dioxin Table 2 for explanation for equivocal entries). ND = not determined; n.a. = not assigned; a = yes in rat liver but no in human endometrium: no (estrogen-receptor mediated); b = Non-genotoxic MoA but genotoxic metabolite. Nitrogen mustards include: (3) HN1 = bis(2-chloroethyl)ethylamine HN2 = bis(2-chloroethyl) methylamine HN3 = tris(2-chloroethyl)amine+ their hydrochlorides. Table 1 .
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(TCDD)] mechanisms and not expected to be data-rich with regard to genotoxicity (19) . Data were obtained by searching published literature via dedicated search engines such as Toxline (https://toxnet.nlm.nih.gov/newtoxnet/ toxline.htm or PubMed (https://www.ncbi.nlm.nih.gov/pubmed), as well as searching the NTP database (https://ntp.niehs.nih.gov/pubhealth/roc/) and the Gold 'Carcinogenic Potency Database' (CPDB, https://toxnet.nlm.nih.gov/cpdb/). The main search key words were 'CAS# OR chemical name (IUPAC-name)' AND 'genotox*' OR 'mutagen*' OR 'micronucle*'. Moreover, the endpoints 'clastogen*', 'UDS', 'comet Assay', 'Transgenic', and 'Pig-a' were used as key words in combination with the chemical or CAS number. The search keywords were also used with wildcards (*). Depending on the specific properties of the chemicals, we considered the p.o. and/or inhalation routes of administration to rats and mice as most relevant, but also included i.p. and i.v. routes. We recorded data from all organs investigated, including the hematopoietic system (bone marrow, peripheral blood), liver, gastrointestinal tract (stomach, gut), and bladder. For the in vivo MN test, erythrocytes (bone marrow or peripheral blood) was considered the target tissue. In cases where more than two organs in a study showed a carcinogenic response, we defined the respective test compound as a 'multi-organ' carcinogen. Differences with regard to rodent strains used or duration of treatment were not taken into account as long as the requirements of applicable regulatory guidance documents were fulfilled. The outcomes of the chemicals are summarised in tabular form (Table 1 and Supplementary Table 1 , available at Mutagenesis Online).
Analyses
We looked for correlations of qualitative calls between in vivo genotoxicity endpoints versus human carcinogens (IARC 1 and 2A). Conclusions from the individual in vivo genotoxicity test results (positive, negative, equivocal calls) (summarised in Table 1 and listed  with corresponding references in Supplementary Table 1, available at Mutagenesis Online) were generally accepted as given in the literature, provided that the studies had been conducted according to the state of the art i.e. in accordance to the relevant test guidelines or recommended best practices available at the time of publication. This means that studies that were conducted with non-standard protocols (e.g. very young rats, which were used in a MN test for o-toluidine) were not considered in the overall conclusions. Positive (POS) and negative (NEG) calls in the table describe final assessments concluded by the authors of this manuscript. In case several studies exist for the same study type, a final call was based on a weight of evidence assessment, considering the validity and strength of the individual results, which may be positive as well as negative. A 'result' refers to the outcome of a single genotoxicity assay.
An equivocal (EQV) call was assigned when the chemical showed ambiguous, doubtful, questionable results (equally likely to be positive or negative) within a study. In keeping with Kirkland et al., 'Equivocal calls were also given if the data across different publications showed both positive and negative findings and where the weight of evidence did not allow a clear positive or negative overall call' (20) . Chemicals which we considered to have equivocal outcomes are listed and discussed in Table 2 .
In the evaluation, clear positive findings (POS) were assigned a value of one. EQV results would usually require follow-up testing; therefore, for the purpose of this analysis we considered them positive, according to common regulatory practice, and also assigned a value of one. Negative (NEG) results were assigned a value of zero. If no data were available for a specific genotoxic endpoint or a specific organ, this is indicated in the table as 'no data' (ND). An assay for which there were no data was not assigned a number and was not further considered for any calculation or correlation. The calculation of sensitivity was according to equation 1, where the total tested was the sum of POS, EQV and NEG:
Caveats to the analysis
The calculations that we have made describe the sensitivity of an assay to detect Group 1 and 2A carcinogens. Although being an important step in cancer development, it is acknowledged that the genotoxicity resulting from direct DNA interaction is just one of several causes for cancer induction and that several of the Group 1 and 2A carcinogens possess a generally accepted non-genotoxic MoA. Also, since no non-carcinogens are available in this database, the specificity (correct prediction of a non-carcinogen) and the overall predictive capacity of an assay cannot be calculated.
Results and Discussion
General observations: assay use frequency and distribution statistics
A total of 73 IARC group 1 and 2A chemicals were reviewed for the availability and outcome of in vivo genotoxicity studies. Five different in vivo test assays were included in this evaluation: the MN, comet, TGR mutation, liver UDS and Pig-a assays. The most frequently used in vivo test assay was the MN assay, in which 66 chemicals (90% of the total reviewed) were tested. Approximately half (52%) of the chemicals were tested in the comet assay (38 of the 73 IARC chemicals) and the TGR mutation assay (31 chemicals, 42%). The rat liver UDS assay was used for testing of 14 chemicals (19%) and the rodent Pig-a assay was used to test 17 chemicals (23%). The number of different in vivo test assays used per chemical was evaluated. Six of the 73 chemicals were not tested in any of the in vivo genotoxicity assays. These were 1-(2-chloroethyl)-3cyclohexyl-1-nitrosourea, bis-(chloromethyl)ether, captafol, chlorozotocin, dibenz[a,j] acridine and vinyl fluoride. All these chemicals are nevertheless considered by IARC to be genotoxic carcinogens based on their structure, knowledge of mutagenic potential of analogues and positive in vitro data. Approximately half of the chemicals (38 in total) have been tested in one or two in vivo test models and the remaining 29 chemicals in three or more in vivo test models. Six chemicals were tested in all five in vivo assays. Unsurprisingly, these six are well-known research chemicals often used during development of new test methods and/ or used as positive controls, namely 1,2-dimethylhydrazine, acrylamide, benzo[a]pyrene, cyclophosphamide, N-nitrosodiethylamine and methyl methanesulfonate. In many cases, the same chemical was tested more than once in the same assay, e.g. several in vivo MN studies have been conducted, using different rodent species and/or strains.
Sensitivity of single in vivo genotoxicity assays
The numbers of IARC chemicals tested positive, negative or equivocal per test assay are shown in Figure 1 . Since genotoxicity is considered the key MoA for the vast majority of IARC Group 1 and 2A chemicals, a high prevalence of positive findings in the in vivo genotoxicity assays was expected.
The percentage of negative results (false negatives) was highest for the UDS assay (36% of the 14 chemicals tested), followed by the (55) . Since there are similar numbers of positive and negative studies and we were unable to weight them meaningfully with regards to their quality/guideline compliance, we concluded the overall result for this chemical to be 'equivocal'.
Acrylamide-in vivo Pig-a test There are two published studies in which acrylamide was tested in the Pig-a assay. It is suggested that the genotoxicity of this chemical is tissuespecific, based on a study in rats in which it caused DNA damage in the liver (measured using the comet assay), but was not a clastogen and only a weak (equivocal) mutagen as measured by the Pig-a assay in bone marrow cells (27) . In the second study, male rats and mice were given acrylamide in drinking water for 30 days (28) . In rats, acrylamide was negative and equivocal for MN formation and mutations, respectively; whereas, in mice, positive and negative results were reported for the MN test and Pig-a assay, respectively. The authors suggested that the genotoxic MoA is related to structural DNA damage rather than point mutations. Since no firm conclusions can be drawn from these studies we have considered acrylamide as equivocal in the Pig-a assay.
Tetrachloroethylene-in vivo liver comet assay Investigations on tetrachloroethylene are complicated by its controversial MoA (Table 4 ). This chemical has been the subject of extensive discussions not necessarily because different studies showed different results but because a different interpretation of the same data in one study can be made depending on the statistical analysis (56) . Additional complications of artefacts due to workup practices of comet assay samples (in the order low to mid-to high doses) leading to dose-related correlations not related to DNA damage have also been shown to impact the interpretation of data (Struwe et al., (57) ). Since there was no conclusive outcome from the analysis by Lovell et al. (56) , we classified it as equivocal.
Indium phosphide-in vivo MN test
The genotoxicity of this chemical is thought to be via non-genotoxic mechanisms (Table 4) . In a 14-week study carried out by the NTP, the frequency of micronuclei was determined in the peripheral blood of mice exposed to indium phosphide by inhalation (58) . There were no significant increases in the frequencies of micronucleated normochromatic erythrocytes of male or female mice; however, micronucleus formation was observed in the polychromatic erythrocytes of male but not in female mice (59) . While the NTP concluded this to be an overall negative result, we considered it to be equivocal for our evaluation.
2-Naphthylamine-in vivo MN test A total of nine studies are available for 2-naphthylamine and, although many of them are not fully compliant with today's standards, their results are considered valid. Top doses were between 100 and 800 mg/kg body weight (in rats, mice and via oral gavage or i.p.). Five of the studies were reported negative, three positive and one equivocal. Due to the scarcity of available details, it remains a matter of speculation to decide which of these results should be considered most relevant and we therefore classified the call to be equivocal.
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-in vivo MN test
Two literature references were evaluated for the MN induction by NNK: one laboratory reports a dose-related increase of MN in bone marrow of mice following administration of 500 mg/kg (i.p., twice) (60) . For NNK, a negative MN result was indicated in the literature (8) , referring to a secondary publication (61); however, both references lack any information on this endpoint. Based on these results we classified the call to be equivocal.
4,4′-Methylenebis(2-chloroaniline) (MOCA)-in vivo MN test
In MN studies with MOCA using different mouse strains both negative and weakly positive results were reported after i.p. administration (21) . The authors considered the overall results as inconclusive, corresponding to an 'equivocal' call according to the evaluation criteria in our report. Like other aromatic amines, MOCA undergoes metabolic activation by liver CYPs via initial formation of the N-hydroxy-MOCA, which can bind to DNA or can be further activated to an N-sulfate ester by liver sulfotransferases (62) . Genotoxic effects in vivo with MOCA would be expected in the tissue of origin of the DNA-reactive metabolites, i.e. the liver. The equivocal effects seen in the mouse bone marrow studies may thus be due to insignificant exposure to the genotoxic metabolites. This view is supported by the outcome of the mouse comet assay which was clearly positive in the liver and bladder but negative in bone marrow. The results indicate that the difference between the clearly positive comet assay and the equivocal MN test is due to differences in tissue sensitivity (as a result of differences in exposure) rather than sensitivity of the endpoints measured.
Dimethylcarbamoyl chloride-in vivo MN test This was considered to be equivocal due to conflicting results from three studies, two of which were positive and one was negative (63) (64) (65) . Dimethylcarbamoyl chloride is highly unstable in an aqueous environment, and therefore has a low bioavailability after systemic exposure. This is supported by carcinogenicity data showing benign and malignant skin tumours (papilloma and carcinoma) but no tumours in other organs. Exposure by s.c. or i.p. injection caused tumours at the injection site (sarcoma) only (66) .
N-Nitrosodimethylamine-in vivo MN test
N-Nitrosodimethylamine was considered in our evaluation to be equivocal in the bone marrow MN test. It is known that bone marrow is not sufficiently exposed to the active metabolites of some pro-mutagens due to their short lifespan, resulting in poor detectability of micronucleus induction. Therefore, the liver, the main organ of metabolism, is a prime target for evaluation of such chemicals. N-nitrosodimethylamine is an example of such a chemical, such that it was positive for micronuclei formation in the liver but not in the peripheral blood of rats (67) .
in vivo MN test (26% of the 66 chemicals tested), the Pig-a assay (18% of the 17 tested), the TGR (10% of the 31 tested) and the comet assay (8% of the 38 chemicals tested). The overall sensitivity of the individual assays (calculated according to equation 1) showed an interesting distinction between single-tissue (MN, Pig-a, UDS) versus multi-tissue assays (comet and TG). The sensitivities of the single-tissue in vivo assays, MN, UDS and Pig-a, were 74.2, 64.3 and 82.4%, respectively; whereas the sensitivities of the multi-tissue in vivo assays, comet and TGR, were 92.1 and 90.3%, respectively (Table 3) . A positive correlation between the number of tissues investigated and sensitivity appears biologically plausible; however, the observed difference in sensitivity between in vivo MN test and multitissue assays may be biased by a lack of overlap of chemicals tested in the different systems. The relative sensitivities of the in vivo genotoxicity assays are discussed in more detail in the following sections.
Rodent erythrocyte MN data
A total of 66 human IARC Group 1 and 2A carcinogens have been identified for which published in vivo erythrocyte MN data exist. Fortynine of the 66 human carcinogens (74.2%) were positive or equivocal in the in vivo MN test (Table 3 ). The remaining 17 negative carcinogens produced negative results in the in vivo MN test. Of these 17 chemicals, three are generally acknowledged to induce tumours via a nongenotoxic MoA (TCDD, cyclosporine A and gallium arsenide; Table 4 ). There are several other chemicals with possible non-genotoxic MoAs but which are not discussed further here since their non-genotoxic MoAs are controversial and not generally acknowledged (Table 4) . Considering all 17 MN negative carcinogens altogether (Table 5) Overall, the above analysis shows adequate sensitivity of the in vivo MN assay for detecting human carcinogens. When the four carcinogens with an established non-genotoxic MoA are excluded from the calculation, 48 out of 62 carcinogens were found positive or equivocal in the MN assay resulting in a sensitivity of 77.4%. This number is higher than that reported by Morita et al. (21) who stated a sensitivity of 68.6 and 54.5% for IARC 1 and 2A carcinogens, respectively, and also higher than that reported by Bhagat (22) , who calculated a sensitivity of 70% for the in vivo MN assay to detect IARC 1 carcinogens. This difference can be explained by the difference in the used IARC datasets-for the present manuscript the analysis was restricted to individual chemicals, everything else was considered less tangible (such as complex mixtures, physical agents) and was excluded from our analysis (see 'Data collection' section). The negative MN results seen with some of the genotoxic carcinogens are most likely due to insufficient systemic distribution of (i) short-lived, reactive genotoxic metabolites in cases where the carcinogens require hepatic metabolic activation or (ii) 'direct acting' genotoxicants that may react more or less completely with tissues at sites-of-first-contact e.g. formaldehyde. In both cases, the ultimate genotoxic species may not reach the bone marrow in sufficient amounts to induce detectable effects in the MN test. As these limitations of the bone marrow MN assay are long known, the actual version of the MN testing guideline (OECD 474) requires proof of bone marrow exposure of the substance in question. Alternatively, some guidelines [e.g. International Council for Harmonisation (ICH) for pharmaceuticals] supplement the in vivo MN assay with a second in vivo test capable of detecting genotoxic effects directly in the liver and/or in other tissues (e.g. the potential site-of-first-contact). The appropriate choice of the second in vivo assay and tissue mainly depends on the profile of the in vitro findings regarding endpoint-specificities and need for metabolic activation (see section on 'Combination of test models' for further discussion).
Rat liver UDS data
A total of 14 human IARC Group 1 and 2A carcinogens (all with a genotoxic MoA) were identified for which published rat liver UDS data exist. Nine of the 14 human carcinogens (64.3%) were positive (Table 3) ; the remaining five carcinogens produced negative results in the UDS test. All UDS positive carcinogens were also detected by the TGR and/or comet assays. These values are conservative since they include the four carcinogens generally acknowledged to be non-genotoxic. Note that not all chemicals were tested in each assay. Of the five negative chemicals in the UDS test, two (trichloroethylene, 1,2,3-trichloropropane) showed negative results also in other in vivo assays. Trichloroethylene was negative in the MN, comet and TGR assays and 1,2,3-trichloropropane was negative in the MN test. The remaining three UDS negative chemicals (benzo[a] pyrene, cyclophosphamide, acrylamide) were readily detected in the comet and TG assays. Taking into account all analysed in vivo genotoxicity data for the 73 IARC 1 and 2A carcinogens, while showing adequate overall sensitivity, the liver UDS assay does not provide relevant added value in detecting chemical carcinogens compared to the other in vivo tests. There is no single case where a carcinogen would have been missed by the combination of the in vivo MN test with the comet or TGR assay, but would have been detected by the UDS assay. In an earlier comparison of in vivo genotoxicity assays to detect (liver) rodent carcinogens that were 'missed' in the in vivo MN assay, the UDS test showed a poor sensitivity of detecting the carcinogens as compared to a much higher sensitivity of the comet and TGR assays (23) . Our data analysis does not confirm such a clear difference in the assay sensitivities -most probably due to the differences in the datasets analysed. In recent revisions of guidelines, such as the ICH S2R1, the rat liver UDS test has been replaced as the preferred complement to the 'standard' in vivo MN assay by the liver comet assay. Our data analysis confirms that the comet assay is an appropriate replacement of the UDS test since it would significantly improve the predictivity if performed in combination with the in vivo MN test while the UDS assay does not (see section on 'Combination of test models' for further discussion).
TGR assay data
A total of 31 human IARC Group 1 and 2A carcinogens have been identified for which published TGR assay data exist. Twenty-eight of the 31 human carcinogens (90.3%) were positive (Table 3) ; the remaining three carcinogens produced negative results in the TGR test. If TCDD is excluded from the calculation (non-genotoxic MoA, see below), the sensitivity is 93.3% (28 out of 30). Of the 28 chemicals that tested positive in the TGR assay, negative results are reported in one or more of the other four in vivo test models in 9 cases (MN: N-nitrosodiethylamine, 1,2 dibromoethane and IQ; comet when including all organs: none; comet in liver only: thiotepa; phenacetin; Pig-a: 1,2-dimethyhydrazine; UDS: benzo[a] pyrene; cyclophosphamide; acrylamide). There were three chemicals that were positive in the TGR that were equivocal in other The tumourigenic MoA of GaAs in lung is probably linked to particulate-induced inflammation and increased proliferation in the lung (69). GaAs did not induce micronucleus formation but the 'liberation' of dissolved As and Ga ions from the crystalline GaAs lead to higher exposures which seems to result in DNA damage via indirect mechanisms (oxidative stress, inhibition of DNA repair enzyme activity) following sub-chronic administration (70) . In addition, there is evidence from in vitro test systems that ionic gallium, such as the gallium transferrin complex, may influence the carcinogenic process by inducing apoptosis at low doses (71) . Indium phosphide Inhalation of indium phosphide causes pulmonary inflammation that progresses to atypical hyperplasia and neoplasia in the lungs of rats (59) . Evidence indicates an association between oxidative stress and inflammation, possibly leading to lung neoplasia as the mode of carcinogenic action for indium phosphide. It has been suggested that apoptotic stress responses may trigger repair associated cell proliferation contributing to the risk for the development of neoplasia (59) .
Carcinogens with controversial MoAs
Phenacetin Phenacetin-induced necrosis of the urothelium followed by increased cell proliferation rather than direct mutagenicity is considered to be the key mechanism in human and animal tumour formation (72) . This view is supported by negative findings with phenacetin in the transgenic p53 mouse bioassay, a test model known to be specifically sensitive towards carcinogens with a genotoxic MoA (72) .
The MoA of trichloroethylene has been a research subject for decades and continues to be a matter of debate. Trichloroethylene was consistently negative in all analysed endpoints. However, there is good evidence that the carcinogenicity of trichloroethylene is related to its complex metabolism. A simplified summary can be described as following: subsequent to glutathione-conjugation in the liver, primary metabolites are further processed in the kidney and can form highly reactive secondary species that can react with DNA. The metabolism is highly variable across sex, species and organ. A number of non-genotoxic MoAs like accumulation of α2μ-globulin, peroxisome proliferation, oxidative stress, nephrotoxicity/cytotoxicity are also being discussed and the complexity of the carcinogenic MoA of trichloroethylene is generally acknowledged (73) (74) (75) (76) (77) (78) (79) (80) . The situation is further complicated by the role of the epichlorhydrin-impurity, as mentioned in the IARC monograph (81) . An in-depth analysis was not performed since this exceeds the scope of the present manuscript. Tetrachloroethylene Tetrachloroethylene (and/or its metabolites) was negative or equivocal in analysed endpoints in several tissues of both rats and mice. A statistical evaluation of in vivo comet assay results in mice for this chemical gave no conclusive outcome (56) and the metabolism of this chemical is also considered rather complex. The hepatocarcinogenic effect is attributed to a Peroxisome Proliferator-Activated Receptor (PPAR) mediated MoA while kidney tumours are hypothesised to be related to alpha-2μ-globulin accumulation and/or cytotoxic effects. A genotoxic MoA, especially for kidney cancer, can however not be ruled out given the formation of mutagenic metabolites (45, (82) (83) (84) (85) .
tests [(4-(methylnitrosamino)-1-(3-pyrridyl)-1-(butanone) (NNK)
and N-nitrosodimethylamine in the MN test and acrylamide in the Pig-a assay]. Assuming that the positive result is the correct outcome, this comparison suggests a comparatively good sensitivity of the TGR model. The three chemicals with negative results in the TGR assay were TCDD, etoposide and trichloroethylene. As TCDD belongs to the few IARC group 1 and 2A carcinogens with accepted non-genotoxic MoA (24) the negative findings in the TGR assay can be considered correct. This is further supported by a negative in vivo MN test with TCDD. Etoposide is a potent mammalian topoisomerase II inhibitor and, as such, is expected to be a strong clastogen rather than inducing gene mutations. The in vivo data profile with positive in vivo MN and comet assay results and a negative outcome in the TGR assay is in line with this mechanistic view. Nevertheless etoposide has been shown to be positive in the Ames test and the CHO HPRT assay (25) , indicating that it can induce gene mutations at least under in vitro conditions. The negative result with trichloroethylene in the TGR assay is in accordance with negative findings in the in vivo MN, comet and UDS tests.
Pig-a assay data
A total of 17 human IARC Group 1 and 2A carcinogens have been identified for which published Pig-a data exist (all of which had a genotoxic MoA). Fourteen of the 17 human carcinogens (82.4%) were positive or equivocal (Table 3 ) and the remaining three carcinogens produced negative results in the Pig-a assay. Most of the carcinogens found positive in the Pig-a assay also showed positive results in one or more of the other in vivo assays with the exception of two chemicals that produced negative responses in the UDS test (benzo[a]pyrene, cyclophosphamide) and one in the MN assay (N-nitrosodiethylamine). The negative result with N-nitrosodiethylamine in the MN assay is likely due to insufficient exposure of the bone marrow to the genotoxic liver-derived metabolites (liver UDS, comet, TGR assays were all positive). Although having the same target tissue (bone marrow) the apparently higher sensitivity of the Pig-a over the MN assay may be due to the fact that effects in the Pig-a can accumulate with repeated dosing over a prolonged period of time which is not the case with the MN assay (26) .
We classified acrylamide as equivocal in the Pig-a assay based on two studies. A dose-dependent induction of Pig-a mutant red blood cells in rats following oral gavage was reported by Dobrovolsky et al. (27) . By contrast, a negative result was reported in the Pig-a assay in mice administered acrylamide in drinking water for 30 days (in the same mice, there was a dose-dependent increase in micronucleus formation) (28) . Acrylamide was positive in the MN, comet, TGR assays and negative in the UDS test (Table 1) .
There were three chemicals that were negative in the rodent Pig-a assay, namely 1,2-dimethylhydrazine, 4-chloro-o-toluidine and etoposide. 1,2-Dimethylhydrazine produced positive results in all of the other four in vivo assays; 4-chloro-o-toluidine was positive in the comet assay and negative in the MN test; and etoposide was positive in the MN test and comet assay and negative in the TGR assay. There is a species difference in the tumourigenicity of 4-chloro-o-toluidine, such that there is no incidence of tumours in the rat but evidence of multiple tumours in mice (hemangiosarcomas and hemangioma mainly in the spleen and adipose tissue) (Supplementary Table 1 , available at Mutagenesis Online). This would account for the reported negative result for 4-chloro-o-toluidine in the Pig-a assay performed in rats (unpublished data). There are no Pig-a studies performed in mice, which seems to be the most relevant species for the induction of tumours. Etoposide has a predominantly clastogenic MoA (a topoisomerase II inhibitor) and therefore cannot be reliably identified using this assay.
Comet assay data
A total of 38 human IARC Group 1 and 2A carcinogens have been identified for which published comet assay data exist. Thirty-five of the 38 human carcinogens (92.1%) produced positive results (Table 3 ) and the remaining three carcinogens were negative in the comet assay. By excluding gallium arsenide and indium phosphide from the calculation (both act most likely via a non-genotoxic MoA, but were positive in the comet assay), the sensitivity changes marginally (to 91.7%, 33 out of 36). Of the 35 carcinogens that produced positive results in the comet assay, 19 compounds were also positive or equivocal in one or more of the other in vivo assays and nine compounds showed mixed positive or negative results in the other in vivo assays. Six compounds were negative in one or more of the other in vivo assays. These were: 4-chloro-o-toluidine with negative results in the MN and Pig-a assays; formaldehyde, gallium arsenide, o-toluidine, styrene-7,8-oxide and vinyl bromide with a negative result each in the MN assay. As gallium arsenide is considered to induce tumours via a non-genotoxic MoA the isolated positive comet assay finding is unexpected and may be considered a 'false-positive'.
Two carcinogens that produced negative results in the comet assay are also negative in the other in vivo assays: chloramphenicol was negative in the MN assay and trichloroethylene was negative in the MN, UDS, and TGR assays. Melphalan was positive in the MN test and in the Pig-a assay. Although melphalan was negative in the standard comet assay, it was positive in the 'cross-linker protocol' in which X-ray in vitro irradiation showed the presence of melphalan-induced cross-links in bone marrow cells (29) . This shows that the sensitivity of the comet assay can be increased if the test chemical is suspected of being a cross-linker (OECD, 2014). In our analysis, the comet assay showed the highest sensitivity in detecting carcinogens among the in vivo models considered. This observation is in agreement with the outcome of a comparison of the sensitivity of the comet assay to the UDS and TGR assays in detecting MN-negative or equivocal rodent carcinogens where the comet assay showed the highest sensitivity (23) .
Sensitivity of combination of test systems
The in vivo MN test, to date, has been the most widely used in vivo genotoxicity test and is considered in all regulatory guidelines either as part of a standard battery or for follow-up testing of positive in vitro results. Its wide use is also reflected in the present analysis where published MN assay data were available for 66 of the 73 (90%) IARC group 1 and 2A carcinogens and thus showed the highest test coverage. It is well known that the MN assay has limitations in detecting certain relevant genotoxicants, particularly when short-lived hepatic metabolites or effects at sites-of-first-contact are involved (e.g. OECD 474). For this reason, it has been common practice to require proof of exposure or to complement the in vivo MN assay with a second in vivo test. In order to assess what might be the most appropriate complement to the in vivo MN test to detect IARC group 1 and 2A carcinogens, the sensitivity of the combination with the comet assay, the TGR assay and the Pig-a assay have been evaluated.
In vivo MN test in bone marrow + comet assay in liver
Out of a total of 73 of the IARC Group 1 and 2A chemicals, 65 were considered to have a genotoxic MoA. Of these, 31 were tested in the in vivo MN test in bone marrow and the comet assay in liver (Table 1) . A combination of these two assays detects (defined as: 'positive in at least one of the two endpoints') 93.5% of these (29 out of 31 genotoxic carcinogens tested in these assays). By including two chemicals with a non-genotoxic mechanism that were also tested in both assays (gallium arsenide, indium phosphide), the sensitivity slightly increases to 93.9% (31 out of 33). Ten compounds were detected (positive or equivocal) with the liver comet assay but not with the in vivo MN: gallium arsenide, formaldehyde, styrene-7,8-oxide, 1,2-dibromethane, tetrachloroethylene, N-nitrosodiethylamine, vinyl bromide, IQ, o-toluidine and 4-chloro-o-toluidine (Supplementary Table 1 , available at Mutagenesis Online). One of the Group 1 and 2A carcinogens is reported to be negative in both tests, epichlorhydrin. Epichlorhydrin, administered via i.p. injection, was judged by the authors as being negative in the liver comet assay, but positive in stomach and lung (10, 30) . Looking at the original data presented in (30) ; however, the tail length in liver increased from 1.42% in the control animals to 7.23% in treated animals at the time point 8 h after treatment-a 5-fold increase. This increase happens at the same time point at which epichlorhydrin was showing the strongest effect in the stomach and lung. It would, however, not be missed even if it was not easily detected in the liver since epichlorhydrin was considered positive in two other organs and therefore was rated positive overall (Table 1) . To note, the above discussed high sensitivity of a combination of the in vivo MN assay with the comet assay to detect IARC Group 1 and 2A carcinogens (93.9%) bases on assessing liver only while comet studies performed for regulatory purposes will usually also evaluate additional tissue(s), e.g. the tissue at the site-of-first-contact. however, a non-genotoxic mechanism is thought to play a role in their carcinogenicity (Table 4) .
In vivo MN test in bone marrow +TGR in various tissues
In vivo MN test in bone marrow +Pig-a
There were only two chemicals that were negative in the MN test which were also tested in the Pig-a assay. N-Nitrosodiethylamine was negative the in vivo MN test but is detected by the Pig-a assay; however, 4-chloro-o-toluidine was not detected in the Pig-a assay. The combination of in vivo MN and Pig-a tests detects 94.1% (16 of 17) of the IARC Group 1 and 2A chemicals (all of which had a genotoxic MoA). Since this number is based on the evaluation of only two chemicals that were negative in the in vivo MN, a more comprehensive assessment of the utility of the Pig-a will require additional data.
Overall evaluation of assay combinations
It has already been demonstrated that combining two or more in vitro endpoints considerably increases the sensitivity to predict rodent carcinogens (31, 32) and holds true also for the in vivo data presented here. This is can be explained with the underlying biology (different genotoxicity endpoints and tissues investigated), but very likely also by probability, i.e. there is a higher chance of detecting the effects of a potential genotoxicant when multiple assays and/or tissues are analysed. All evaluated combinations of the in vivo MN test with one additional assay resulted in an increased sensitivity of 93% or higher (Table 3) . While demonstrating excellent sensitivity, the presented dataset does not allow one to draw conclusions about the specificity of each assay or assay combination since our focus was on IARC 1 and 2A, hence, no non-carcinogens have been evaluated in this study. The sensitivity of the TGR and the comet assays has been evaluated by Kirkland et al. (23) as a complement to the in vivo MN test and were reported to capture 61% and 89%, respectively, of all rodent carcinogens that are missed by the in vivo MN test, while we found a sensitivity of 90.3 and 91.9% for IARC 1 and 2A carcinogens, respectively. Based on the much higher sensitivity of the comet and TGR assays when compared to the in vivo UDS assay, these are now given a more prominent role in regulatory testing (2).
Site-of-first-contact
The so-called 'direct acting' genotoxicants do not require metabolic activation to exert their DNA damaging properties and are often highly chemically reactive e.g. formaldehyde. They therefore show higher sensitivity in the tissue(s) of highest exposure, which is usually the siteof-first-contact. It has been speculated that their genotoxic potential could be missed in assays that do not allow for assessing the tissue of first contact, which, depending on the route of exposure, will usually be the GI tract (oral exposure), skin (topical exposure), or the nasal/ bronchial/alveolar epithelium (inhalation exposure). Increased attention to site-of-first-contact effects is evidenced by recent changes in the regulatory guidelines. For example, the ICH guideline S2R1 mentions that experiments which examine effects at the site-of-first-contact 'can be warranted' (2). The Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) Guidance on information requirements for chemical safety assessment specifically mentions that highly electrophilic chemicals with positive results in vitro, particularly in the absence of metabolic activation, may possibly only exert their mutagenic potential at the initial site-of-first-contact (33) . These changes in regulatory guidelines go hand-in-hand with an increased emphasis on the ability of the comet and TGR tests to better address potential siteof-first-contact effects, as described in the recently developed OECD test guidelines OECD 489 and 488 (34, 35) . More specifically, both guidelines mention that the potential for site-of-first-contact effects should be considered when selecting the tissues to be examined, which is in line with earlier claims that these assays are particularly useful in evaluating directly-acting genotoxicants at their initial site of action (6, 11, 36) . Similar efforts are also underway for the in vivo MN test where a methodology has recently been developed to assess the glandular stomach as a site-of-first-contact tissue (37, 38) . Data for a site-of-first-contact tissue (stomach or gut) was available for 8 of the IARC 1 and IARC 2A DNA reactive carcinogens not needing metabolic activation (there were 35 direct genotoxicants in total). These were ethyl-N-nitrosourea, epichlorhydrin, etoposide, methyl methanesulfonate, N-methyl-N′-nitro-N-nitrosoguanidine, N-nitroso-N-methylurea, styrene-7,8-oxide and formaldehyde. All 8 of these chemicals were positive in the gut or stomach in the comet and/or the TGR tests. This shows an excellent predictivity for these assays at the site-of-first-contact. Surprisingly there was a high predictivity (93%) at the site-of-first-contact also for carcinogens needing metabolic activation (14 out of 15 for which site-offirst-contact data were available were positive, see Supplementary Table 1 , available at Mutagenesis Online). Furthermore, all of the chemicals (whether requiring metabolic activation, or not) which were positive in the stomach and/or gut were also positive in one or more other organ. Overall, the data observed for the comet and/ or the TGR tests confirm that these assays are suitable for assessing the genotoxicity of chemicals acting on site-of-first-contact organs. However, systemic in vivo tests also showed positive results, probably due to the strong potency of the compounds under investigation which probably induce systemic toxic effects even at low(er) concentrations than those at which genotoxic effects were observed.
The use of site-of-first-contact approaches may be more critical for less potent direct acting genotoxicants since they might be missed at distant sites where exposure will be lower. An example of this is formaldehyde, which produces DNA monoadducts, DNA-DNA and DNA-protein cross-links only at initial sites of contact (39) . In accordance with this, formaldehyde produced positive results in stomach, colon, lung, kidney, and bladder cells of mice after 8 or 24 h after single oral exposure (10), while negative results were reported for peripheral blood of rats after 28-days inhalation (40) . Despite this, one study measured comet formation in lymphocytes and liver cells of rats exposed 5 and 10 ppm formaldehyde by inhalation for 2 weeks (41). The authors reported a very similar dose-related increase in DNA migration in both cell types. This study was queried (42) for two main reasons: First of all, formaldehyde induces DNA-protein crosslinks but not DNA strand breaks and thus also fails to induce measurable DNA migration in the standard alkaline comet assay (43) . Secondly, due to its very reactive nature, systemic effects of formaldehyde after inhalation exposure are unlikely; therefore, it was surprising that increased DNA migration was measured in formaldehyde-exposed rats and similar effects were observed in liver cells and lymphocytes. Figure 2 . The hematopoietic system is the most frequent human cancer site (62.5%, 20 out of 32 chemicals), followed by urinary bladder (25%, 8 out of 32); whereas the remaining 12 tissues identified are less frequent targets for human cancer (all < 10%). Given these proportions combined with the fact that leukaemias have often been associated with chromosomal aberrations (44), we will discuss the correlation of in vivo MN genotoxicity results with lymphoma/leukaemia in humans in more detail. For the remaining tissues, there was only limited data available and no clear correlation between genotoxicity positive tissues and cancerbearing organs could be observed. This might be related to a number of factors, including (i) the limited set of organs investigated for genotoxicity endpoints in animal studies compared to a larger number of cancer sites observed in humans, (ii) differences in the dose level (usually higher dose levels are used for in vivo genotoxicity studies as compared to rodent carcinogenicity studies, or human exposure), duration of the genotoxicity assays (usually short term studies) and route of exposure, and (iii) the limited number of chemicals with sufficient data for both in vivo genotoxicity and human carcinogenicity.
Lymphoma/leukaemia represent the most frequently observed human cancers induced by IARC Group 1 chemicals (44); therefore, we evaluated the ability of the in vivo MN test to detect early events related to the development of these cancers (i.e. MN) caused by 20 of the chemicals in our dataset. Overall, 70.0% of those respective chemicals (14 out of 20 tested substances) were detected positively by the in vivo MN test in bone marrow. The negative MN results for the remaining six chemicals (TCDD, cylosporin A, formaldehyde, trichloroethylene chloramphenicol, and tetrachloroethylene) can be explained by taking into account their carcinogenic MoA and chemical properties: two chemicals are accepted as having non-genotoxic MoA, namely TCDD and cyclosporin A (Table 4) ; formaldehyde is chemically reactive and typically does not reach the bone marrow but induces effects at the so called 'site-of-first-contact' (39, 40, 42) . For tetrachloroethylene and trichloroethylene, only limited evidence for carcinogenicity in humans is available while their presumed MoA is rather complex Figure 2 . IARC chemicals (n = 32) with sufficient or limited evidence of carcinogenicity in humans. Distribution of cancer sites (some chemicals with more than one cancer site). Ly/Leu, lymphoma and/or leukaemia; Bl, urinary bladder; K, kidney, renal pelvis and ureter; Li, Liver and bile duct; Lu, lung; S, skin; Br, breast; En, endometrium; Na, Nasopharynx; St, soft tissue; V, vagina; Uc, uterine cervix; T, testis; Es, esophagus. and a matter of extended debate that goes beyond the scope of the present study (45, 46) . Chloramphenicol has a very complex in vitro genotoxicity dataset showing mostly negative in the Ames assay (47) and mixed results in in vitro mammalian assays, with DNA breaks and chromosomal aberrations being reported in a fraction these studies (47, 48) and it is therefore impossible to come to a firm conclusion on its genotoxic potential and the carcinogenic MoA. If the two chemicals with an accepted non-genotoxic MoA are excluded (namely TCDD and cyclosporin A), the sensitivity is increased to 77.7% (14 out of 18). It is concluded that the in vivo MN test in bone marrow has a good sensitivity for substances that cause hematopoietic cancers in humans.
Conclusions
• 73 IARC group 1 and 2A chemicals were considered for this analysis, 66 of which had in vivo genotoxicity data. The majority of these chemicals had been tested in the in vivo MN test, half in the in vivo comet and TGR assays; and only ~20% in the in vivo UDS assay and the relatively new Pig-a assay. Most chemicals had been tested in 1-2 assays and there were six chemicals that had been tested in all five assays, mainly because they are used as positive control chemicals in these assays.
• Although the MN test is mainly used to detect clastogens and aneugens and generally not thought to be sensitive for gene mutations, our data evaluation shows that 21 out of 26 TGR positive carcinogens also tested positive in the MN test. This observation concurs with the well-known fact that strong DNA-reactive carcinogens can typically induce both, chromosome aberrations and gene mutations.
• The overall sensitivities of multi-organ assays [comet (92%) and TGR (90%)] were higher than those of the single organ assays (MN, UDS, Pig-a-64 to 82%); however, the observed difference in sensitivity may be biased by the limited dataset (number of chemicals studied, and number of chemicals tested across two or more assays). Of the chemicals that did overlap between assays (20 in total), 15 carcinogens that were negative or equivocal in the in vivo MN test in rodents were positive in a second in vivo assay, mainly the comet assay. The in vivo MN does not detect carcinogens that are not bioavailable in the bone marrow or have a non-genotoxic MoA; however, it is capable of identifying the majority of human carcinogens, and therefore remains a useful part of the evaluation of genotoxicity of chemicals. • Combining two endpoints increases the overall sensitivity.
Addition of the comet, TGR and Pig-a assays to the in vivo MN test increased the sensitivity to 93% or higher. The addition of the comet or TGR assays would identify all DNA reactive human carcinogens (IARC 1A), and the addition of the Pig-a would identify 96.6% of all DNA reactive human carcinogens. The combination of the in vivo MN test with the Pig-a assay or TGR would allow for the differentiation between clastogenic/aneugenic and mutagenic MoA mechanisms, respectively. • In keeping with the 3Rs principle (i.e. reduce, replace, refine), if the MN test in peripheral blood is combined with the Pig-a both endpoints are obtainable in the same study with minimal invasiveness as animals only need to be bled but not euthanised. In addition, since the two assays are rather specific for clastogenic/ aneugenic and mutagenic MoA, respectively, they would furthermore allow for differentiation between these general mechanisms.
• OECD 489 and 488 test guidelines suggested that the potential for site-of-contact effects should be considered when selecting the tissues to be examined. Therefore, we addressed whether the comet assay was more sensitive/useful for so-called 'site-of-first-contact organs' than in the liver (as recommended in ICH guideline). Based on the data available for IARC Group 1 and 2A chemicals, there is no need for the inclusion of site-of-first-contact tissues into a study. All chemicals for which site-of-first-contact data were available (a total of 26) would have been correctly identified by investigating the chemicals' genotoxic activity in two nonsite-of-first-contact organs, i.e. in the liver and the hematopoietic system (bone marrow or peripheral blood).
• Based on the small number of chemicals with multi-organ genotoxicity in our dataset, there was only limited correlation between organ-specificity for genotoxicity and organ-specificity for carcinogenicity. The only striking correlation observed was for the in vivo MN test which exhibits a good sensitivity for detecting chemicals that cause hematopoietic cancers in humans (78% of IARC Group 1 chemicals). The addition of comet data does not improve this correlation any further.
Supplementary data
Supplementary Table 1 is available at Mutagenesis Online.
